Manuel Munuera Cabeza

Mr. Manuel Munuera Cabeza


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 February 2021 in Antioxidants
Verified
Journal Article
Open access
PDF file
JSJuan Miguel Suárez-Rivero
Juan Miguel Suárez-Rivero
CPCarmen Julia Pastor-Maldonado
Carmen Julia Pastor-Maldonado
SPSuleva Povea-Cabello
Suleva Povea-Cabello
MCMónica Álvarez Córdoba
Mónica Álvarez Córdoba
IVIrene Villalón
Irene Villalón
José A Sanchez AlcazarJosé A Sanchez Alcazar
José A Sanchez Alcazar
Coenzyme Q10 (CoQ10 or ubiquinone) is a mobile proton and electron carrier of the mitochondrial respiratory chain with antioxidant properties widely used as an antiaging health supplement and to relieve the symptoms of many pathological conditions associated with mitochondrial dysfunction. Even though the hegemony of CoQ10 in the context of antioxidant-based treatments is undeniable, the future primacy of this quinone is hindered by the promising features of its numerous analogues. Despite the unimpeachable performance of CoQ10 therapies, problems associated with their administration and intraorganismal delivery has led clinicians and scientists to search for alternative derivative molecules. Over the past few years, a wide variety of CoQ10 analogues with improved properties have been developed. These analogues conserve the antioxidant features of CoQ10 but present upgraded characteristics such as water solubility or enhanced mitochondrial accumulation. Moreover, recent studies have proven that some of these analogues might even outperform CoQ10 in the treatment of certain specific diseases. The aim of this review is to provide detailed information about these Coenzyme Q10 analogues, as well as their functionality and medical applications.

Verified
Journal Article
Open access
PDF file
CPCarmen Julia Pastor-Maldonado
Carmen Julia Pastor-Maldonado
JSJuan Miguel Suárez-Rivero
Juan Miguel Suárez-Rivero
SPSuleva Povea-Cabello
Suleva Povea-Cabello
MCMónica Álvarez Córdoba
Mónica Álvarez Córdoba
IVIrene Villalón
Irene Villalón
José A Sanchez AlcazarJosé A Sanchez Alcazar
José A Sanchez Alcazar
The aim of this review is to shed light over the most recent advances in Coenzyme Q10 (CoQ10) applications as well as to provide detailed information about the functions of this versatile molecule, which have proven to be of great interest in the medical field. Traditionally, CoQ10 clinical use was based on its antioxidant properties; however, a wide range of highly interesting alternative functions have recently been discovered. In this line, CoQ10 has shown pain-alleviating properties in fibromyalgia patients, a membrane-stabilizing function, immune system enhancing ability, or a fundamental role for insulin sensitivity, apart from potentially beneficial properties for familial hypercholesterolemia patients. In brief, it shows a remarkable amount of functions in addition to those yet to be discovered. Despite its multiple therapeutic applications, CoQ10 is not commonly prescribed as a drug because of its low oral bioavailability, which compromises its efficacy. Hence, several formulations have been developed to face such inconvenience. These were initially designed as lipid nanoparticles for CoQ10 encapsulation and distribution through biological membranes and eventually evolved towards chemical modifications of the molecule to decrease its hydrophobicity. Some of the most promising formulations will also be discussed in this review.

13 December 2023 in Biomolecules
Verified
Journal Article
Open access
PDF file
PHPaula Cilleros Holgado
Paula Cilleros Holgado
DGDavid Gómez-Fernández
David Gómez-Fernández
RPRocío Piñero-Pérez
Rocío Piñero-Pérez
JRJose Manuel Romero-Domínguez
Jose Manuel Romero-Domínguez
DRDiana Reche-López
Diana Reche-López
José A Sanchez AlcazarJosé A Sanchez Alcazar
José A Sanchez Alcazar
Mitochondria play a key role in cellular functions, including energy production and oxidative stress regulation. For this reason, maintaining mitochondrial homeostasis and proteostasis (homeostasis of the proteome) is essential for cellular health. Therefore, there are different mitochondrial quality control mechanisms, such as mitochondrial biogenesis, mitochondrial dynamics, mitochondrial-derived vesicles (MDVs), mitophagy, or mitochondrial unfolded protein response (mtUPR). The last item is a stress response that occurs when stress is present within mitochondria and, especially, when the accumulation of unfolded and misfolded proteins in the mitochondrial matrix surpasses the folding capacity of the mitochondrion. In response to this, molecular chaperones and proteases as well as the mitochondrial antioxidant system are activated to restore mitochondrial proteostasis and cellular function. In disease contexts, mtUPR modulation holds therapeutic potential by mitigating mitochondrial dysfunction. In particular, in the case of neurodegenerative diseases, such as primary mitochondrial diseases, Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD), Amyotrophic Lateral Sclerosis (ALS), or Friedreich’s Ataxia (FA), there is a wealth of evidence demonstrating that the modulation of mtUPR helps to reduce neurodegeneration and its associated symptoms in various cellular and animal models. These findings underscore mtUPR’s role as a promising therapeutic target in combating these devastating disorders.

5 March 2021 in Biomedicines
Verified
Journal Article
Open access
PDF file
JSJuan Miguel Suárez-Rivero
Juan Miguel Suárez-Rivero
CPCarmen Julia Pastor-Maldonado
Carmen Julia Pastor-Maldonado
SPSuleva Povea-Cabello
Suleva Povea-Cabello
MCMónica Álvarez Córdoba
Mónica Álvarez Córdoba
IVIrene Villalón
Irene Villalón
José A Sanchez AlcazarJosé A Sanchez Alcazar
José A Sanchez Alcazar
Inflammation is a key process in metazoan organisms due to its relevance for innate defense against infections and tissue damage. However, inflammation is also implicated in pathological processes such as atherosclerosis. Atherosclerosis is a chronic inflammatory disease of the arterial wall where unstable atherosclerotic plaque rupture causing platelet aggregation and thrombosis may compromise the arterial lumen, leading to acute or chronic ischemic syndromes. In this review, we will focus on the role of mitochondria in atherosclerosis while keeping inflammation as a link. Mitochondria are the main source of cellular energy. Under stress, mitochondria are also capable of controlling inflammation through the production of reactive oxygen species (ROS) and the release of mitochondrial components, such as mitochondrial DNA (mtDNA), into the cytoplasm or into the extracellular matrix, where they act as danger signals when recognized by innate immune receptors. Primary or secondary mitochondrial dysfunctions are associated with the initiation and progression of atherosclerosis by elevating the production of ROS, altering mitochondrial dynamics and energy supply, as well as promoting inflammation. Knowing and understanding the pathways behind mitochondrial-based inflammation in atheroma progression is essential to discovering alternative or complementary treatments.

17 July 2021 in Biomolecules
Verified
Journal Article
Open access
PDF file
JSJuan Miguel Suárez-Rivero
Juan Miguel Suárez-Rivero
CPCarmen Julia Pastor-Maldonado
Carmen Julia Pastor-Maldonado
SPSuleva Povea-Cabello
Suleva Povea-Cabello
MCMónica Álvarez Córdoba
Mónica Álvarez Córdoba
IVIrene Villalón
Irene Villalón
José A Sanchez AlcazarJosé A Sanchez Alcazar
José A Sanchez Alcazar
The discovery and application of antibiotics in the common clinical practice has undeniably been one of the major medical advances in our times. Their use meant a drastic drop in infectious diseases-related mortality and contributed to prolonging human life expectancy worldwide. Nevertheless, antibiotics are considered by many a double-edged sword. Their extensive use in the past few years has given rise to a global problem: antibiotic resistance. This factor and the increasing evidence that a wide range of antibiotics can damage mammalian mitochondria, have driven a significant sector of the medical and scientific communities to advise against the use of antibiotics for purposes other to treating severe infections. Notwithstanding, a notorious number of recent studies support the use of these drugs to treat very diverse conditions, ranging from cancer to neurodegenerative or mitochondrial diseases. In this context, there is great controversy on whether the risks associated to antibiotics outweigh their promising beneficial features. The aim of this review is to provide insight in the topic, purpose for which the most relevant findings regarding antibiotic therapies have been discussed.

13 November 2020 in Diseases
Verified
Journal Article
Open access
PDF file
IVIrene Villalón
Irene Villalón
MCMónica Álvarez Córdoba
Mónica Álvarez Córdoba
JSJuan Miguel Suárez-Rivero
Juan Miguel Suárez-Rivero
SPSuleva Povea-Cabello
Suleva Povea-Cabello
MTMarta Talaverón-Rey
Marta Talaverón-Rey
José A Sanchez AlcazarJosé A Sanchez Alcazar
José A Sanchez Alcazar
Rare diseases are those that have a low prevalence in the population (less than 5 individuals per 10,000 inhabitants). However, infrequent pathologies affect a large number of people, since according to the World Health Organization (WHO), there are about 7000 rare diseases that affect 7% of the world’s population. Many patients with rare diseases have suffered the consequences of what is called the diagnostic odyssey, that is, extensive and prolonged serial tests and clinical visits, sometimes for many years, all with the hope of identifying the etiology of their disease. For patients with rare diseases, obtaining the genetic diagnosis can mean the end of the diagnostic odyssey, and the beginning of another, the therapeutic odyssey. This scenario is especially challenging for the scientific community, since more than 90% of rare diseases do not currently have an effective treatment. This therapeutic failure in rare diseases means that new approaches are necessary. Our research group proposes that the use of precision or personalized medicine techniques can be an alternative to find potential therapies in these diseases. To this end, we propose that patients’ own cells can be used to carry out personalized pharmacological screening for the identification of potential treatments.